Factor Xa inhibitors versus vitamin K antagonists for preventing cerebral or systemic embolism in patients with atrial fibrillation

Cochrane Database of Systematic Reviews

Volumn 2018, Issue 3, 2018, Pages

  Bruins Slot, Karsten M H ^a   Berge, Eivind ^a  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVITAMIN K; APIXABAN; BETRIXABAN; BLOOD CLOTTING FACTOR 10A INHIBITOR; DAREXABAN; EDOXABAN; IDRABIOTAPARINUX; IDRAPARINUX; RIVAROXABAN; WARFARIN; VITAMIN K GROUP;

ALL CAUSE MORTALITY; ANTICOAGULANT THERAPY; ATRIAL FIBRILLATION; BLEEDING; BRAIN EMBOLISM; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CEREBROVASCULAR ACCIDENT; CHADS2 SCORE; DRUG EFFICACY; DRUG SAFETY; DRUG USE; EMBOLISM; FATALITY; HEART INFARCTION; HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SYSTEMATIC REVIEW; SYSTEMIC DISEASE; VASCULAR DISEASE; ANTAGONISTS AND INHIBITORS; COMPLICATION; META ANALYSIS;

ATRIAL FIBRILLATION; EMBOLISM; FACTOR XA INHIBITORS; HUMANS; INTRACRANIAL EMBOLISM; RANDOMIZED CONTROLLED TRIALS AS TOPIC; STROKE; VITAMIN K;

EID: 85032895766     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD008980.pub3     Document Type: Review

References (72)

1. The Amadeus Investigators. Comparison of idraparinux with vitamin K antagonists for prevention of thromboembolism in patients with atrial fibrillation: a randomised, open-label, non-inferiority trial. Lancet 2008;371:315-21. 3064545
2. Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, et al. Apixaban versus warfarin in patients with atrial fibrillation. New England Journal of Medicine 2011;365:981-92. 3064547
3. Ogawa S, Shinohara Y, Kanmuri K. Safety and efficacy of the oral direct factor Xa inhibitor apixaban in Japanese patients with non-valvular atrial fibrillation. Circulation Journal 2011;75:1852-9. 3064549
4. Buller HR, Halperin J, Hankey GJ, Pillion G, Prins MH, Raskob GE. Comparison of idrabiotaparinux with vitamin K antagonists for prevention of thromboembolism in patients with atrial fibrillation: the Borealis-Atrial Fibrillation Study. Journal of Thrombosis and Haemostasis 2014;12(6):824-30. 3064551
5. Chung N, Jeon HK, Lien LM, Lai WT, Tse HF, Chung WS, et al. Safety of edoxaban, an oral factor Xa inhibitor, in Asian patients with non-valvular atrial fibrillation. Thrombosis and Haemostasis 2011;105:535-45. 7754334
6. Yamashita T, Koretsune Y, Yasaka M, Inoue H, Kawai Y, Yamaguchi T, et al. Randomized, multicenter, warfarin-controlled phase II study of edoxaban in Japanese patients with non-valvular atrial fibrillation. Circulation Journal 2012;76:1840-7. 3064555
7. Weitz JI, Connolly SJ, Patel I, Salazar D, Rohatagi S, Mendell J, et al. Randomised, parallel-group, multicentre, multinational phase 2 study comparing edoxaban, an oral factor Xa inhibitor, with warfarin for stroke prevention in patients with atrial fibrillation. Thrombosis and Haemostasis 2010;104:633-41. 3064557
8. Giugliano RP, Ruff CT, Braunwald E, Murphy SA, Wiviott SD, Halperin JL, et al. Edoxaban versus warfarin in patients with atrial fibrillation. New England Journal of Medicine 2013;369:2093-104. 3064559
9. Connoly SJ, Eikelboom J, Dorian P, Hohnloser SH, Gretler DD, Sinha U, et al. Betrixaban compared with warfarin in patients with atrial fibrillation: results of a phase 2, randomized, dose-ranging study (Explore-Xa). European Heart Journal 2013;34(20):1498-505. [DOI: 10.1093/eurheartj/eht/039]3064561
10. Hori M, Matsumoto M, Tanahashi N, Momomura SI, Uchiyama S, Goto S, J-ROCKET AF study investigators. Rivaroxaban vs warfarin in Japanese patients with atrial fibrillation. Circulation Journal 2012;76(9):2104-11. [DOI: 10.1253/circj.CJ-12-0454]3064563
11. Turpie AGGF, Lip GYH, Minematsu K, Goto S, Renfurm RW, Wong KSL. Safety and tolerability of YM150 in subjects with non-valvular atrial fibrillation: a phase II study. European Heart Journal 2010;31 Suppl 1:173. 3064565
12. Lip GYH, Halperin JL, Petersen P, Rodger GM, Renfurm RW. Safety and tolerability of the oral factor Xa inhibitor YM150 vs warfarin in 1297 patients with non-valvular atrial fibrillation: a dose confirmation study (OPAL-2). Journal of Thrombosis and Haemostatis 2011;9 Suppl 2:748. 3064567
13. Patel MR, Mahaffey KW, Garg Y, Pan G, Singer DE, Hacke W, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. New England Journal of Medicine 2011;365:883-91. 3064569
14. BAY59-7936. ClinicalTrials.gov. 3064573
15. Camm AJ, Bounameaux H. Edoxaban: a new oral direct factor Xa inhibitor. Drugs 2011;71(12):1503-26. 3064579
16. Connolly SJ, Eikelboom J, Joyner C, Diener HC, Hart R, Golitsyn S, et al. Apixaban in patients with atrial fibrillation. New England Journal of Medicine 2011;364(9):806-17. 3064583
17. Harenberg J. Idraparinux and idrabioparinux. Expert Review of Clinical Pharmacology 2010;3(1):9-16. 3064607
18. Lopes RD, Alexander JH, Al-Khatib SM, the ARISTOTLE investigators. Apixaban for reduction in stroke and other thromboembolic events in atrial fibrillation (ARISTOTLE) trial: design and rationale. American Heart Journal 2010;159(3):331-9. 3064627
19. Partida RA, Guigliano RP. Edoxaban: pharmacological principles, preclinical and early-phase clinical testing. Future Cardiology 2011;7(4):459-70. 3064635
20. ROCKET AF Study Investigators. Rivaroxaban once-daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation: rationale and design of the ROCKET AF study. American Heart Journal 2010;159(3):340-7. 3064639
21. Study synopsis. 3064645
22. January CT, Wann LS, Alpert JS, Calkins H, Cleveland JC, Cigarroa JE, et al. Guidelines for the management of patients with atrial fibrillation. Circulation 2014; Vol. 129. [DOI: 10.1161/CIR.000000000000000041]
23. Almutairi A, Zhou L, Lee JK, Marion S, Martin JR, Lo-Ciganic W. Comparative effectiveness and safety of novel oral anticoagulants (NOACS) versus vitamin K antagonists (VKA) in atrial fibrillation: a meta-analysis of observational studies. Value Health 2016;3(19):A41.
24. Biondi-Zoccai G, Malavasi V, D'Ascenzo F, Abbate A, Agostoni P, Lotrionte M, et al. Comparative effectiveness of novel oral anticoagulants for atrial fibrillation: evidence from pair-wise and warfarin-controlled network meta-analyses. HSR Proceedings in Intensive Care and Cardiovascular Anesthesia 2013;5(1):40-54.
25. Boulanger L, Kim J, Friedman M, Hauch O, Foster T, Menzin J. Patterns of use of antithrombotic therapy and quality of anticoagulation monitoring among patients with non-valvular atrial fibrillation in clinical practice. International Journal of Clinical Practice 2006;60:258-64.
26. Caldeira D, Rodrigues FB, Barra M, Santos AT, de Abreu D, Goncalves N. Non-vitamin K antagonist oral anticoagulants and major bleeding-related fatality in patients with atrial fibrillation and venous thromboembolism: a systematic review and meta-analysis. Heart 2015;15(101):1204-11.
27. Cameron C, Coyle D, Richter T, Kelly S, Gauthier K, Steiner S, et al. Systematic review and network meta-analysis comparing antithrombotic agents for the prevention of stroke and major bleeding in patients with atrial fibrillation. BMJ Open 2014;4(6):e004301. [DOI: 10.1136/bmjopen-2013-004301]
28. Capodanno D, Capranzano P, Giacchi G, Calvi V, Tamburino C. Novel oral anticoagulants versus warfarin in non-valvular atrial fibrillation: a meta-analysis of 50, 578 patients. International Journal of Cardiology 2013;167(4):1237-41. [DOI: 10.1016/j.ijcard.2012.03.148]
29. Gage BF, Waterman AD, Shannon W, Boechler M, Rich MW, Radford MJ. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA 2001;285(22):2864-70.
30. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
31. Connolly SJ, Eikelboom J, O'Donnell M, Pogue J, Yusuf S. Challenges of establishing new antithrombotic therapies in atrial fibrillation. Circulation 2007;116:449-55.
32. Connolly SJ, Pogue J, Eikelboom J, Flaker G, Commerford P, Franzosi G, the ACTIVE W Investigators. Benefit of oral anticoagulant over antiplatelet therapy in atrial fibrillation depends on the quality of International Normalized Ratio control achieved by centers and countries as measured by time in therapeutic range. Circulation 2008;118:2029-37.
33. Deeks JJ, Altman DG, Bradburn MJ. Statistical methods for examining heterogeneity and combining results from several studies in meta-analysis. In: Egger M, Davey Smith G, Altman DG editor(s). Systematic Reviews in Health Care. Meta-analysis in Context. London: BMJ Books, 2001:285-312.
34. Dogliotti A1, Paolasso E, Giugliano RP. Novel oral anticoagulants in atrial fibrillation: a meta-analysis of large, randomized, controlled trials vs warfarin. Clinical Cardiology 2013;36(2):61-7. [DOI: 10.1002/clc.22081]
35. Heidbuchel H, Verhamme P, Alings M, Antz M, Hacke W, Oldgren J, et al. European Heart Rhythm Association practical guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation. Europace 2013;15:625-51.
36. Eikelboom JW, Weitz JI. New anticoagulants. Circulation 2010;121:1523-32.
37. Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B, et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. European Heart Journal 2016;37:2893-962.
38. Fu W, Guo H, Guo J, Lin K, Wang H, Zhang Y, et al. Relative efficacy and safety of direct oral anticoagulants in patients with atrial fibrillation by network meta-analysis. Journal of Cardiovascular Medicine 2014;12(15):873-9.
39. Garg J, Chaudhary R, Krishnamoorthy P, Palaniswamy C, Shah N, Bozorgnia B, et al. Safety and efficacy of oral factor-Xa inhibitors versus vitamin K antagonist in patients with non-valvular atrial fibrillation. International Journal of Cardiology 2016;218:235-9.
40. Go AS, Hylek EM, Philips KA, Henault, LE, Selby JV, Singer DE. Prevalence of diagnosed atrial fibrillation in adults. National implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA 2001;285:2370-5.
41. Gomez-Outes A, Suarez-Gea ML, Terleira-Fernandez AI, Vargas-Castrillon E, Calvo-Rojas G. Direct oral anticoagulants versus warfarin for stroke prevention in atrial fibrillation: a subgroup meta-analysis in European patients. Clinical Therapeutics 2015;37(8 Suppl):e10.
42. Haim M, Hoshen M, Reges O, Rabi Y, Balicer R, Leibowitz M. Prospective national study of the prevalence, incidence, management and outcome of a large contemporary cohort of patients with incident non-valvular atrial fibrillation. Journal of the American Heart Association 2015;4:e001486.
43. Hankey GJ, Patel MR, Stevens SR, Becker RC, Breithardt G, Carolei A. Rivaroxaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of ROCKET AF. Lancet Neurology 2012;11:315-22.
44. Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have non-valvular atrial fibrillation. Annals of Internal Medicine 2007;146:857-67.
45. Heeringa J, Van der Kuip DA, Hofman A, Kors JA, Van Herpen G, Stricker BH, et al. Prevalence, incidence and lifetime risk of atrial fibrillation: the Rotterdam study. European Heart Journal 2006;27:949-53.
46. Henriksson KM, Farahmand B, Asberg S, Edvardsson N, Terent A. Comparison of cardiovascular risk factors and survival in patients with ischemic or hemorrhagic stroke. International Journal of Stroke 2012;7:276-81.
47. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
48. Hylek EM, Evans-Molina C, Shea C, Henault LE, Regan S. Major haemorrhage and tolerability of warfarin in the first year of therapy among elderly patients with atrial fibrillation. Circulation 2007;115:2689-96.
49. Kirchhof P, Auricchio A, Bax J, Crijns H, Camm J, Diener H-C, et al. Outcome parameters for trials in atrial brillation: executive summary. Recommendations from a consensus conference organized by the German Atrial Fibrillation Competence NETwork (AFNET) and the European Heart Rhythm Association (EHRA). European Heart Journal 2007;28:2803-17.
50. Krijthe BP, Kunst A, Benjamin EJ, Lip GY, Franco OH, Hofman A, et al. Projections on the number of individuals with atrial fibrillation in the European Union, from 2000 to 2060. European Heart Journal 2013;34:2746-51.
51. Kwong JS, Lam YY, Yan BP, Yu CM. Bleeding of new oral anticoagulants for stroke prevention in atrial fibrillation: a meta-analysis of randomized controlled trials. Cardiovascular Drugs and Therapy 2013;27(1):23-35. [DOI: 10.1007/s10557-012-6426-9]
52. Lega JC, Mismetti P, Cucherat M, et al. Impact of double-blind vs. open study design on the observed treatment effects of new oral anticoagulants in atrial fibrillation: a meta-analysis. Journal of Thrombosis and Haemostasis 2013;11(7):1240-50. [DOI: 10.1111/jth.12294]
53. Lin L, Lim WS, Zhou HJ, Khoo AL, Tan KT, Chew AP, et al. Clinical and safety outcomes of oral antithrombotics for stroke prevention in atrial fibrillation: a systematic review and network meta-analysis. Journal of the American Medical Directors Association 2015;16(12):1103.e1-19.
54. Lip GYH, Mitchell SA, Liu X, Liu LZ, Phatak H, Kachroo S, et al. Relative efficacy and safety of non-Vitamin K oral anticoagulants for non-valvular atrial fibrillation: network meta-analysis comparing apixaban, dabigatran, rivaroxaban and edoxaban in three patient subgroups. Internaitonal Journal of Cardiology 2016;204:88-94.
55. Liu L, Weber B, Oesterle A, Nayak HM, Upadhyay GA. A meta-analysis of the efficacy, effectiveness, and safety of novel oral anticoagulants compared with vitamin K antagonists for stroke prevention in atrial fibrillation. Heart Rhythm 2016;1:S599.
56. Lloyd-Jones DM, Wang TJ, Leip EP, Larson MG, Levy D, Vasan RS, et al. Lifetime risk for development of atrial fibrillation: the Framingham heart study. Circulation 2004;110:1042-6.
57. Marini C, De Santis F, Sacco S, Russo T, Olivieri L, Totaro R, et al. Contribution of atrial fibrillation to incidence and outcome of ischemic stroke. Results from a population study. Stroke 2005;36:1115-9.
58. Mitchell SA, Simon TA, Raza S, Jakouloff D, Orme ME, Lockhart I, et al. The efficacy and safety of oral anticoagulants in warfarin-suitable patients with nonvalvular atrial fibrillation: systematic review and meta-analysis. Clinical and Applied Thrombosis/Hemostasis 2013;19(6):619-31. [DOI: 10.1177/1076029613486539]
59. Miyasaki Y, Barnes ME, Gersh BJ, Cha SS, Bailey KR, Abhayaratna WP, et al. Secular trends in incidence of atrial fibrillation in Olmsted County, Minnesota, 1980 to 2000, and implications on the projection for future prevalence. Circulation 2006;114:119-25.
60. Morimoto T, Crawford B, Wada K, Ueda S. Comparative efficacy and safety of novel oral anticoagulants in patients with atrial fibrillation: a network meta-analysis with the adjustment for the possible bias from open label studies. Journal of Cardiology 2015;66(6):466-74.
61. Mousa SA. Oral direct factor Xa inhibitors, with special emphasis on rivaroxaban. Anticoagulants, Antiplatelets, and Thrombolytics. Springer Science+Business Media, 2010:181-201.
62. Pisters R, Lane DA, Nieuwlaat R, De Vos CB, Crijns HJ, Lip GY. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: The Euro Heart Survey. Chest 2010;138(5):1093-100.
63. Providência R, Grove EL, Husted S, Barra S, Boveda S, Morais J. A meta-analysis of phase III randomized controlled trials with novel oral anticoagulants in atrial fibrillation: comparisons between direct thrombin inhibitors vs. factor Xa inhibitors and different dosing regimens. Thrombosis Research 2014;134(6):1253-64. [DOI: 10.1016/j.thromres.2014.10.002]
64. The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014.
65. Ruff CT, Giugliano RP, Braunwald E, Hoffman EB, Deenadayalu N, Ezekowitz MD, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet 2014;15(383):955-62. [DOI: 10.1016/S0140-6736(13)62343-0]
66. Sudlow C, Rodgers H, Kenny RA, Thomson R. Population-based study of the use of anticoagulants among patients with atrial fibrillation in the community. BMJ 1997;314:1529-30.
67. Tahir F, Riaz H, Riaz T, Badshah MB, Riaz IB, Hamza A, et al. The new oral anti-coagulants and the phase 3 clinical trials - a systematic review of the literature. Thrombosis Journal 2013;11(1):18.
68. Tawfik A, Bielecki JM, Krahn M, Dorian P, Hoch JS, Boon H, et al. Systematic review and network meta-analysis of stroke prevention treatments in patients with atrial fibrillation. Clinical Pharmacology 2016;8:93-107.
69. Watson T, Shantsila E, Lip GYH. Mechanisms of thrombogenesis in atrial fibrillation: Virchow's triad revisited. Lancet 2009;373:155-66.
70. Wattigney WA, Mensah GA, Croft JB. Increasing trends in hospitalisation for atrial fibrillation in the United States, 1985 through 1999: implications for primary prevention. Circulation 2003;108:711-6.
71. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke 1991;22:983-8.
72. Xiang CL, Gong YZ, Zeng LJ, Wang R, Kea S, Chaudhary N, et al. Efficacy and safety or oral direct factor Xa inhibitors versus warfarin in patients with atrial fibrillation: a meta-analysis of randomized controlled trials. Acta Cardiologica 2016;71(3):349-57.